Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print.ABSTRACTNot available.PMID:38497158 | DOI:10.3324/haematol.2023.284109

Source: Haematologica - March 18, 2024 Category: Hematology Authors: Emilio Iannitto Simone Ferrero C ôme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord G Source Type: research